Growth differentiation factor 15: a biomarker searching for an indication
- PMID: 36459111
- DOI: 10.1093/eurheartj/ehac681
Growth differentiation factor 15: a biomarker searching for an indication
Conflict of interest statement
Conflict of interest: C.M. has received research support from the Swiss National Science Foundation, the Swiss Heart Foundation, the KTI, the University Hospital Basel, the University of Basel, Beckman Coulter, Biomerieux, Brahms, Mitsubishi, Novartis, Ortho Clinical, Quidel, Roche, Siemens, Singulex, and Sphingotec, as well as speaker honoraria/consulting honoraria from Astra Zeneca, Bayer, Boehringer Ingelheim, BMS, Osler, Novartis, Roche, Siemens, SpinChip, and Singulex, outside the submitted work, and all paid to the institution. R.A.dB has received research grants and/or fees from AstraZeneca, Abbott, Boehringer Ingelheim, Cardior Pharmaceuticals GmbH, Ionis Pharmaceuticals, Inc., Novo Nordisk, and Roche; and has had speaker engagements with Abbott, AstraZeneca, Bayer, Bristol Myers Squibb, Novartis, and Roche. T.S.M.-G. declares no conflict of interest with this study.
Comment on
-
Growth differentiation factor 15 and cardiovascular risk: individual patient meta-analysis.Eur Heart J. 2023 Jan 21;44(4):293-300. doi: 10.1093/eurheartj/ehac577. Eur Heart J. 2023. PMID: 36303404 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
